Impact of minimum contrast media volumes during percutaneous coronary intervention for chronic total occlusion lesion.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 30 11 2022
accepted: 19 04 2023
medline: 27 7 2023
pubmed: 13 6 2023
entrez: 13 6 2023
Statut: ppublish

Résumé

Contrast media exposure is associated with contrast-induced nephropathy (CIN) following percutaneous coronary intervention (PCI) of chronic total occlusion (CTO). Aim of this study is to assess the utility of minimum contrast media volume (CMV ≤ 50 mL) during CTO-PCI for CIN prevention in patients with chronic kidney disease (CKD). We extracted data from the Japanese CTO-PCI expert registry; 2863 patients with CKD who underwent CTO-PCI performed from 2014 to 2020 were divided into two groups: minimum CMV (n = 191) and non-minimum CMV groups (n = 2672). CIN was defined as an increased serum creatinine level of ≥ 25% and/or ≥ 0.5 mg/dL compared with baseline levels within 72 h of the procedure. In the minimum CMV group, the CIN incidence was lower than that in the non-minimum CMV group (1.0% vs. 4.1%; p = 0.03). Patient success rate was higher and complication rate was lower in the minimum CMV group than in the non-minimum CMV group (96.8% vs. 90.3%; p = 0.02 and 3.1% vs. 7.1%; p = 0.03). In the minimum CMV group, the primary retrograde approach was more frequent in the case of J-CTO = 1,2 and 3-5 groups compared to that in non-minimum CMV-PCI group (J-CTO = 0; 11% vs. 17.7%, p = 0.06; J-CTO = 1; 22% vs. 35.8%, p = 0.01; J-CTO = 2; 32.4% vs. 46.5%, p = 0.01; and J-CTO = 3-5; 44.7% vs. 80.0%, p = 0.02). Minimum CMV-PCI for CTO in CKD patients could reduce the incidence of CIN. The primary retrograde approach was observed to a greater extent in the minimum CMV group, especially in cases of difficult CTO.

Identifiants

pubmed: 37310464
doi: 10.1007/s00380-023-02270-9
pii: 10.1007/s00380-023-02270-9
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1108-1116

Informations de copyright

© 2023. Springer Nature Japan KK, part of Springer Nature.

Références

Tajti P, Karmpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Holper E, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Rangan BV, Ungi I, Banerjee S, Brilakis ES (2018) The hybrid approach to chronic total occlusion percutaneous coronary intervention: update from the PROGRESS CTO registry. JACC Cardiovasc Interv 11:1325–1335
doi: 10.1016/j.jcin.2018.02.036 pubmed: 29706508
Tanaka H, Tsuchikane E, Muramatsu T, Kishi K, Muto M, Oikawa Y, Kawasaki T, Hamazaki Y, Fujita T, Katoh O (2019) A novel algorithm for treating chronic total coronary artery occlusion. J Am Coll Cardiol 74:2392–2404
doi: 10.1016/j.jacc.2019.08.1049 pubmed: 31699280
Harding SA, Wu EB, Lo S, Lim ST, Ge L, Chen JY, Quan J, Lee SW, Kao HL, Tsuchikane E (2017) A new algorithm for crossing chronic total occlusions from the Asia Pacific chronic total occlusion club. JACC Cardiovasc Interv 10:2135–2143
doi: 10.1016/j.jcin.2017.06.071 pubmed: 29122129
Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW (2004) Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93:1515–1519
doi: 10.1016/j.amjcard.2004.03.008 pubmed: 15194023
Patel VG, Brayton KM, Tamayo A, Mogabgab O, Michael TT, Lo N, Alomar M, Shorrock D, Cipher D, Abdullah S, Banerjee S, Brilakis ES (2013) Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv 6:128–136
doi: 10.1016/j.jcin.2012.10.011 pubmed: 23352817
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399
pubmed: 15464318
Ebisawa S, Kurita T, Tanaka N, Nasu K, Kimura M, Ito T, Kinoshita Y, Tsuchikane E, Terashima M, Suzuki T (2016) Impact of minimum contrast media volumes during elective percutaneous coronary intervention for prevention of contrast-induced nephropathy in patients with stable coronary artery disease. Cardiovasc Interv Ther 31:13–20
doi: 10.1007/s12928-015-0337-1 pubmed: 26001976
Suzuki Y, Tsuchikane E, Katoh O, Muramatsu T, Muto M, Kishi K, Hamazaki Y, Oikawa Y, Kawasaki T, Okamura A (2017) Outcomes of percutaneous coronary interventions for chronic total occlusion performed by highly experienced japanese specialists: The first report from the Japanese CTO-PCI Expert Registry. JACC Cardiovasc Interv 10:2144–2154
doi: 10.1016/j.jcin.2017.06.024 pubmed: 29055764
Morino Y, Abe M, Morimoto T, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K, Shibata Y, Hiasa Y, Doi O, Yamashita T, Hinohara T, Tanaka H, Mitsudo K, J-CTO Registry Investigators (2011) Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv 4:213–221
doi: 10.1016/j.jcin.2010.09.024 pubmed: 21349461
Lin YS, Fang HY, Hussein H, Fang CY, Chen YL, Hsueh SK, Cheng CI, Yang CH, Chen CJ, Hang CL, Yip HK, Wu CJ (2014) Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention. EuroIntervention 9:1173–1180
doi: 10.4244/EIJV9I10A198 pubmed: 24561734
Pavlidis AN, Jones DA, Sirker A, Mathur A, Smith EJ (2015) Prevention of contrast-induced acute kidney injury after percutaneous coronary intervention for chronic total coronary occlusions. Am J Cardiol 115:844–851
doi: 10.1016/j.amjcard.2014.12.047 pubmed: 25638517
Lee PH, Lee SW, Park HS, Kang SH, Bae BJ, Chang M, Roh JH, Yoon SH, Ahn JM, Park DW, Kang SJ, Kim YH, Lee CW, Park SW, Park SJ (2016) Successful recanalization of native coronary chronic total occlusion is not associated with improved long-term survival. JACC Cardiovasc Interv 9:530–538
doi: 10.1016/j.jcin.2015.11.016 pubmed: 26947387
Maeremans J, Dens J, Spratt JC, Bagnall AJ, Stuijfzand W, Nap A, Agostoni P, Wilson W, Hanratty CG, Wilson S, Faurie B, Avran A, Bressollette E, Egred B, Knaapen P, Walsh S, RECHARGE Investigators (2017) Antegrade dissection and reentry as part of the hybrid chronic total occlusion revascularization strategy: a subanalysis of the RECHARGE Registry (Registry of CrossBoss and Hybrid Procedures in France, The Netherlands, Belgium and United Kingdom). Circ Cardiovasc Interv 10:e004791
doi: 10.1161/CIRCINTERVENTIONS.116.004791 pubmed: 28625964
Wu EB, Tsuchikane E, Ge L, Harding SA, Lo S, Lim ST, Chen JY, Lee SW, Qian J, Kao HL, Yan BPY (2019) Retrograde versus antegrade approach for coronary chronic total occlusion in an algorithm-driven contemporary Asia-Pacific multicentre registry: comparison of outcomes. Heart Lung Circ 29(6):894–903
doi: 10.1016/j.hlc.2019.05.188 pubmed: 31320259
Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, Cohen HA, Holmes DR Jr, Dynamic Registry Investigators NHLBI (2007) Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 50:584–590
doi: 10.1016/j.jacc.2007.03.058 pubmed: 17692741
Wu EB, Brilakis ES, Mashayekhi K, Tsuchikane E, Alaswad K, Araya M, Avran A, Azzalini L, Babunashvili AM, Bayani B, Behnes M, Bhindi R, Boudou N, Boukhris M, Bozinovic NZ, Bryniarski L, Bufe A, Buller CE, Burke MN, Buttner A, Cardoso P, Carlino M, Chen JY, Christiansen EH, Colombo A, Croce K, de Los Santos FD, de Martini T, Dens J, di Mario C, Dou K, Egred M, Elbarouni B, ElGuindy AM, Escaned J, Furkalo S, Gagnor A, Galassi AR, Garbo R, Gasparini G, Ge J, Ge L, Goel PK, Goktekin O, Gonzalo N, Grancini L, Hall A, Hanna Quesada FL, Hanratty C, Harb S, Harding SA, Hatem R, Henriques JPS, Hildick-Smith D, Hill JM, Hoye A, Jaber W, Jaffer FA, Jang Y, Jussila R, Kalnins A, Kalyanasundaram A, Kandzari DE, Kao HL, Karmpaliotis D, Kassem HH, Khatri J, Knaapen P, Kornowski R, Krestyaninov O, Kumar AVG, Lamelas PM, Lee SW, Lefevre T, Leung R, Li Y, Li Y, Lim ST, Lo S, Lombardi W, Maran A, McEntegart M, Moses J, Munawar M, Navarro A, Ngo HM, Nicholson W, Oksnes A, Olivecrona GK, Padilla L, Patel M, Pershad A, Postu M, Qian J, Quadros A, Rafeh NA, Råmunddal T, Prakasa Rao VS, Reifart N, Riley RF, Rinfret S, Saghatelyan M, Sianos G, Smith E, Spaedy A, Spratt J, Stone G, Strange JW, Tammam KO, Thompson CA, Toma A, Tremmel JA, Trinidad RS, Ungi I, Vo M, Vu VH, Walsh S, Werner G, Wojcik J, Wollmuth J, Xu B, Yamane M, Ybarra LF, Yeh RW, Zhang Q (2021) Global chronic total occlusion crossing algorithm: JACC state-of-the-art review. J Am Coll Cardiol 24:840–853
doi: 10.1016/j.jacc.2021.05.055
Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M, Castaing M, Büttner JH, Bufe A, Kalnins A, Spratt JC, Garbo R, Hildick-Smith D, Elhadad S, Gagnor A, Lauer B, Bryniarski L, Christiansen EH, Thuesen L, Meyer-Geßner M, Goktekin O, Carlino M, Louvard Y, Lefèvre T, Lismanis A, Gelev VL, Serra A, Marzà F, Di Mario C, Reifart N, Club ECTO (2015) Retrograde recanalization of chronic total occlusions in europe: procedural, in-hospital, and long-term outcomes from the multicenter ERCTO Registry. J Am Coll Cardiol 65:2388–2400
doi: 10.1016/j.jacc.2015.03.566 pubmed: 26046732
Megaly M, Ali A, Saad M, Omer M, Xenogiannis I, Werner GS, Karmpaliotis D, Russo JJ, Yamane M, Garbo R, Gagnor A, Ungi I, Rinfret S, Pershad A, Wojcik J, Garcia S, Mashayekhi K, Sianos G, Galassi AR, Burke MN, Brilakis ES (2019) Outcomes with retrograde versus antegrade chronic total occlusion revascularization. Catheter Cardiovasc Interv 96(5):1037–1043
doi: 10.1002/ccd.28616 pubmed: 31778041

Auteurs

Soichiro Ebisawa (S)

Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Hiroyuki Tanaka (H)

Department of Cardiology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki-Shi, Okayama, 710-8602, Japan. ht7307@kchnet.or.jp.

Toshiya Muramatsu (T)

Department of Cardiology, Tokyo Heart Center, Tokyo, Japan.

Koichi Kishi (K)

Department of Cardiology, Tokushima Red Cross Hospital, Tokushima, Japan.

Yuji Oikawa (Y)

The Cardiovascular Institute, Tokyo, Japan.

Makoto Muto (M)

Division of Cardiology, Saitama Prefecture Cardiovascular and Respiratory Center, Saitama, Japan.

Hisayuki Okada (H)

Department of Cardiology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Tomohiro Kawasaki (T)

Department of Cardiology, Shin-Koga Hospital, Fukuoka, Japan.

Ryohei Yoshikawa (R)

Director of Cardiology, Sanda City Hospital, Hyogo, Japan.

Yuji Hamazaki (Y)

Division of Cardiology, Ootakanomori Hospital, Kashiwa, Japan.

Etsuo Tsuchikane (E)

Department of Cardiology, Toyohashi Heart Center, Aichi, Japan.
The Japanese CTO-PCI Expert Foundation, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH